Nicholas Teman
Background: Arterial hypertension remains a significant global health burden, with a substantial proportion of patients experiencing uncontrolled blood pressure despite optimal medical therapy. Renal Denervation (RDN) has emerged as a potential therapeutic modality for such cases, offering a complementary approach to traditional pharmacotherapy.
Objective: This review aims to summarize the current evidence regarding the efficacy, safety, and potential role of renal denervation as a complementary treatment option for patients with uncontrolled arterial hypertension.
Methods: A comprehensive literature search was conducted using electronic databases including Indexed at, Embase, and Cochrane Library. Relevant studies, including randomized controlled trials, observational studies, and systematic reviews, were selected and analyzed.
Results: Several clinical trials and observational studies have demonstrated the efficacy of renal denervation in reducing blood pressure in patients with uncontrolled hypertension. Meta-analyses have shown significant reductions in both office and ambulatory blood pressure following renal denervation procedures. Additionally, RDN appears to have a favorable safety profile, with low rates of procedural complications reported in contemporary studies. However, further research is warranted to elucidate the long-term efficacy and safety of RDN, particularly in diverse patient populations and in comparison with standard medical therapy.
Conclusion: Renal denervation represents a promising complementary treatment option for patients with uncontrolled arterial hypertension despite optimal medical therapy. While current evidence suggests favourable short-term outcomes, ongoing research efforts are necessary to establish its role in routine clinical practice and to refine patient selection criteria and procedural techniques.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 